Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BGB-21447

Small molecule · Inhibitor of B-cell lymphoma 2 (BCL2) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer

What is BGB-21447?

BGB-21447 is an orally bioavailable inhibitor of the anti-apoptotic protein Bcl-2. It binds Bcl-2 and inhibits its activity, restoring apoptosis in tumor cells. It is studied in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
B-cell lymphoma 2 (BCL2)
Mechanism
Inhibitor of B-cell lymphoma 2 (BCL2)
Pathways
apoptosis
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer

Other drugs acting on BCL2

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BGB-21447

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.